Obstructive sleep apnoea, contributed to by the sedating effects of therapeutic drugs and made more likely to be fatal as a result of the patient having moderate coronary atheroma
AI-generated summary
David Muckan, a 49-year-old man with schizophrenia, was admitted to a psychiatric unit in April 1998 with suspected obstructive sleep apnoea (OSA). He was sedated with benzodiazepines (Midazolam, Diazepam) and other psychotropic drugs despite known OSA risk. The coroner found he died from OSA exacerbated by sedating medications and coronary atheroma. Critical deficiencies included inadequate monitoring of a patient with OSA after benzodiazepine administration, poor record-keeping, and lack of continuous visual observation. The coroner noted the hospital lacked protocols for monitoring respiratory status, blood oxygen saturation, and vital signs in such high-risk patients. The case highlights the need for careful risk-benefit analysis when using respiratory-depressant drugs in OSA patients, enhanced monitoring protocols, and documentation standards.
AI-generated summary and tagging — may contain inaccuracies; refer to original finding for legal purposes. Report an inaccuracy.
Specialties
psychiatryrespiratory medicinecardiologyintensive care
Sedating benzodiazepines (Midazolam, Diazepam) administered despite known OSA risk
Thioridazine (Melleril) at therapeutic levels contributing to central nervous system and respiratory depression
Inadequate monitoring of respiratory status and vital signs after benzodiazepine administration
Lack of continuous visual observation of sedated patient
No pulse oximetry monitoring
Moderate coronary artery atherosclerosis
Cumulative sedative effects of multiple psychotropic drugs
Patient found on floor, barely rousable, suggesting over-sedation
Coroner's recommendations
Review of rapid tranquilisation guidelines to ascertain whether they adequately inform clinicians and nurses of the added risks posed by benzodiazepines to sufferers of obstructive sleep apnoea
The Chief Health Officer or Director of Mental Health should take steps to ensure rapid tranquilisation guidelines are adopted in all health care facilities where benzodiazepines are used
Implementation of constant visual observation of sedated patients, particularly those with suspected OSA
Implementation of pulse oximetry monitoring for patients receiving benzodiazepines, particularly those with suspected OSA
Enhanced monitoring protocols including measurement of blood oxygen saturations, pulse rate, respiration rate and blood pressure in patients with OSA receiving benzodiazepines
Improvement of record-keeping systems to ensure legibility of drug administration records
Confirmation that medical officers are notified whenever Midazolam is administered, with specific guidance regarding OSA risk
This page reproduces or summarises information from publicly available findings published by Australian coroners' courts. Coronial is an independent educational resource and is not affiliated with, endorsed by, or acting on behalf of any coronial court or government body.
Content may be incomplete, reformatted, or summarised. Some material may have been redacted or restricted by court order or privacy requirements. Always refer to the original court publication for the authoritative record.
Copyright in original materials remains with the relevant government jurisdiction. AI-generated summaries and tagging are for educational purposes only, may contain inaccuracies, and must not be treated as legal documents. We welcome feedback for correction — report an inaccuracy here.